ALN-PNP / Alnylam, Regeneron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALN-PNP / Alnylam, Regeneron
NCT05648214: A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)

Recruiting
1
96
US
ALN-PNP - Part A, ALN-PNP - Part B, Placebo (PB)
Regeneron Pharmaceuticals
Healthy Volunteers, Non-alcoholic Fatty Liver Disease (NAFLD)
09/25
09/25
NCT06024408: A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Recruiting
1
104
RoW
ALN-PNP, Placebo
Regeneron Pharmaceuticals
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor
09/25
09/25

Download Options